Visiomed is attending Medica in Dusseldorf mid Nov, the...

Visiomed is attending Medica in Dusseldorf mid Nov, the following is just a couple of facts in regards to Funhaler taken from the Austrade site..

..........................................................................


Visiomed develops and commercializes innovative technologies for improved medication delivery and adherence in patients suffering from chronic diseases, initially focusing on the large and growing respiratory diseases market. The worldwide market for respiratory pharmaceuticals and drug delivery is estimated at US$28 billion.

The Funhaler® is currently designed with a patented end piece that allows compatibility without adaptors to major pMDIs (GlaxoSmithKline, AstraZeneca, 3M, Rhone-Poulenc Rorer). This compatibility allows InfaMed to target the greatest potential market share in the paediatric group.

Of the spacer devices currently available in the market, there is no competitive product that has the unique incentive device attachment of the Funhaler®. This invention distinguishes the Funhaler® from other products and allows InfaMed to command a competitive advantage within the market place.



http://www.innovationaustralia.com.au/default.aspx?ArticleID=1832

I hold VSG & VSGO